Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KX2-361 in Subjects With Advanced Malignancies That Are Refractory to Conventional Therapies

NCT02326441 is registered in ClinicalTrials.gov with Athenex, Inc. as lead sponsor.

NCT NCT02326441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02326441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KX2-361 in Subjects With Advanced Malignancies That Are Refractory to Conventional Therapies
Lead sponsor
Athenex, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2014
Completion date
May 23, 2018
Enrollment
29 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advance malignancies